Leading neuroscientists from academia and industry will discuss methodogical aspects of biomarker identification across a spectrum of neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Topics will include strategies for building large biorepositories, technologies for molecular profiling and biomarker discovery, clinical studies of biomarkers in neurologic diseases, and the regulatory approval process.
A preliminary schedule of presentations is attached, and more information may be found at
Tel: 44 (0) 1223 495100
Email: scientificconferences [ at ] hinxton [dot] wellcome [dot] ac [dot] uk
|Biomarkers_2011_Draft_Programme.pdf ||57.53 KB|